VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Feline immunodeficiency virus ORF-A mutant vaccine Feline immunodeficiency virus recombinant vector vaccine FIVΔRT Feline immunodeficiency virus vif mutant vaccine
Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0002959
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Cat
  • ORF-A gene engineering:
    • Type: Gene mutation
    • Description: This ORF-A mutant is from Feline immunodeficiency virus (Pistello et al., 2005).
    • Detailed Gene Information: Click Here.
  • Immunization Route: subcutaneous injection
  • Vaccine Ontology ID: VO_0004550
  • Type: Recombinant vector vaccine
  • Status: Research
  • Vector: replication-defective FIV (Hosie et al., 1998)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0002960
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Cat
  • vif gene engineering:
    • Type: Gene mutation
    • Description: This vif mutant is from feline immunodeficiency virus (Lockridge et al., 2000).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response

Cat Response

Cat Response

  • Vaccination Protocol: Kittens, which were 12 weeks old, were randomized into groups of five for immunization. DNA was administered at four sites in the gastrocnemius and quadriceps muscles (100 μg of each DNA in a total of 200 μl of PBS at each site) (Hosie et al., 1998).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: The bias toward CTL induction rather than antibody production in response to inoculation with FIVΔRT suggested that intramuscular administration of the FIVΔRT DNA generated primarily a Th1-type immune response (Hosie et al., 1998).
  • Challenge Protocol: The cats were challenged with the homologous F-14 molecular clone of the FIV-PET isolate that had been subjected to titer determination by intraperitoneal inoculation of age-matched cats to calculate the 50% infectious dose (Hosie et al., 1998).
  • Efficacy: At 6, 9, and 12 weeks postchallenge, one of five FIVΔRT vaccinates and three of five FIVΔRT-plus-IFN-γ vaccinates remained virus free. In contrast, virus was isolated consistently from all of the control cats (IFN-γ alone and no-DNA control groups) at 6, 9, and 12 weeks postchallenge (Hosie et al., 1998).

Cat Response

References References References
Pistello et al., 2005: Pistello M, Bonci F, Isola P, Mazzetti P, Merico A, Zaccaro L, Matteucci D, Bendinelli M. Evaluation of feline immunodeficiency virus ORF-A mutants as candidate attenuated vaccine. Virology. 2005; 332(2); 676-690. [PubMed: 15680433].
 
Lockridge et al., 2000: Lockridge KM, Chien M, Dean GA, Stefano Cole K, Montelaro RC, Luciw PA, Sparger EE. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology. 2000; 273(1); 67-79. [PubMed: 10891409].